Back to Directory
Degarelix
Performance & EnduranceGnRH antagonist for prostate cancer treatment, provides immediate testosterone suppression.
Key Benefits
- ✓Immediate testosterone suppression
- ✓Treats advanced prostate cancer
- ✓No testosterone flare
- ✓Rapid PSA reduction
- ✓Alternative to agonists
Dosing Information
Dosage Range
80-240 mg
Frequency
Monthly after loading dose
Typical Duration
Ongoing
Detailed Protocol
Administered via subcutaneous injection monthly. Loading dose of 240mg, then 80mg monthly maintenance. Reconstitution required. Medical use only.
About Degarelix
Degarelix (Firmagon) is a synthetic decapeptide GnRH antagonist that provides immediate testosterone suppression without the initial testosterone flare seen with GnRH agonists. FDA-approved for advanced prostate cancer treatment.
Research Notes
FDA-approved in 2008 for prostate cancer. Clinical advantage over agonists is immediate suppression without flare. High rate of injection site reactions.
Potential Side Effects
- •Injection site reactions (very common)
- •Hot flashes
- •Weight gain
- •Fatigue
- •Increased liver enzymes
Always consult with a healthcare professional before starting any peptide therapy.